Argitalpenak (47) MARIA SUSANA BENLLOCH CARRION argitalpenak

2014

  1. Assessing standardization of molecular testing for non-small-cell lung cancer: Results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 413-420

  2. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: Retrospective testing of specimens from the EURTAC trial

    PLoS ONE, Vol. 9, Núm. 2

  3. Gene expression signature of tolerance and lymphocyte subsets in stable renal transplants: Results of a cross-sectional study

    Transplant Immunology, Vol. 31, Núm. 1, pp. 11-16

2012

  1. Gastric cancer

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 90-112

  2. Gastrointestinal stromal tumors

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 7-26

  3. Lung adenocarcinoma

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 136-165

  4. Metastatic melanoma

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 29-49

  5. Ovarian cancer

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 51-73

  6. Pleural mesothelioma

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 115-135

  7. Triple-negative breast cancer

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 75-88

2011

  1. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

    Annals of Oncology, Vol. 22, Núm. 1, pp. 139-144

  2. Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop

    Lung Cancer

  3. MRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer

    Journal of the National Cancer Institute, Vol. 103, Núm. 20, pp. 1552-1556

  4. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

    Clinical Cancer Research, Vol. 17, Núm. 5, pp. 1160-1168

  5. mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.

    Journal of translational medicine, Vol. 9, pp. 163

2010

  1. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

  2. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

    Current Opinion in Oncology, Vol. 22, Núm. 2, pp. 112-120

  3. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain

    Clinical and Translational Oncology, Vol. 12, Núm. 2, pp. 75-80

  4. Predictive biomarkers in the management of EGFR mutant lung cancer

    Annals of the New York Academy of Sciences, Vol. 1210, Núm. 1, pp. 45-52

  5. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer

    PLoS ONE, Vol. 5, Núm. 3